TRPV1 and neuralgia: Posttraumatic sympathetic dystrophy, postmastectomy pain, postherpetic neuralgia, some forms of cancer pain, and other variants of neuropathic pain syndromes maybe addressed with novel adjuvant treatment protocols, planned on our cell-based TRPV1 assays, which may help to select among a number of empirically employed drugs (30+) and rationalize adjuvants' selection.